Last reviewed · How we verify
HP518 - Dose expansion
At a glance
| Generic name | HP518 - Dose expansion |
|---|---|
| Also known as | Part 2 - Dose Expansion Oral tablet(s) |
| Sponsor | Hinova Pharmaceuticals Aus Pty Ltd |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study to Assess the Safety, Pharmacokinetics, and Anti-Tumor Activity of Oral HP518 in mCRPC Patients (PHASE1, PHASE2)
- A Study to Assess the Safety, Pharmacokinetics, and Anti-Tumor Activity of Oral HP518 in Patients With Metastatic Castration-Resistant Prostate Cancer (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- HP518 - Dose expansion CI brief — competitive landscape report
- HP518 - Dose expansion updates RSS · CI watch RSS
- Hinova Pharmaceuticals Aus Pty Ltd portfolio CI